利用18F-FDG PET/CT对乳腺癌新辅助化疗反应进行早期监测：确定临床目标。 - Suppr

Suppr

超能文献

Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

作者信息

Groheux David, Giacchetti Sylvie, Espié Marc, Rubello Domenico, Moretti Jean-luc, Hindié Elif

出版信息

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):419-25. doi: 10.1007/s00259-010-1660-5.

DOI:10.1007/s00259-010-1660-5

PMID:21072510

Abstract

摘要

相似文献

Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):419-25. doi: 10.1007/s00259-010-1660-5.

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

J Nucl Med. 2013 Nov;54(11):1855-6. doi: 10.2967/jnumed.113.126342. Epub 2013 Sep 26.

18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

J Nucl Med. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. Epub 2013 Oct 3.

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.

Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9.

18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.

Q J Nucl Med Mol Imaging. 2014 Mar;58(1):66-73. Epub 2013 Oct 9.

FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1992-3. doi: 10.1007/s00259-010-1585-z. Epub 2010 Aug 11.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.

The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Eur Radiol. 2009 Jun;19(6):1347-57. doi: 10.1007/s00330-009-1303-z. Epub 2009 Feb 13.

18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.

Oncotarget. 2015 Oct 6;6(30):29388-95. doi: 10.18632/oncotarget.5001.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

J Nucl Med. 2015 Jun;56(6):824-31. doi: 10.2967/jnumed.115.154138. Epub 2015 Apr 16.

引用本文的文献

Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: Impact on Early Stage and Outcomes-Comprehensive Review.

Indian J Surg Oncol. 2024 Sep;15(Suppl 3):501-508. doi: 10.1007/s13193-024-02032-7. Epub 2024 Jul 29.

Role of [F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines.

Breast. 2024 Dec;78:103806. doi: 10.1016/j.breast.2024.103806. Epub 2024 Sep 12.

Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in Advanced Breast Cancer by Ultrasound and Clinicopathological Features Using a Nomogram.

Front Oncol. 2021 Nov 23;11:718531. doi: 10.3389/fonc.2021.718531. eCollection 2021.

Update on Quantitative Imaging for Predicting and Assessing Response in Oncology.

Semin Nucl Med. 2020 Nov;50(6):505-517. doi: 10.1053/j.semnuclmed.2020.07.002. Epub 2020 Jul 25.

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.

Cancer Imaging. 2020 Jan 28;20(1):11. doi: 10.1186/s40644-020-0287-4.

AI-based applications in hybrid imaging: how to build smart and truly multi-parametric decision models for radiomics.

Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2673-2699. doi: 10.1007/s00259-019-04414-4. Epub 2019 Jul 11.

Which of the fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography parameters are better associated with prognostic factors in breast cancer?

Medicine (Baltimore). 2019 May;98(22):e15925. doi: 10.1097/MD.0000000000015925.

Influence of age on radiomic features in F-FDG PET in normal breast tissue and in breast cancer tumors.

Oncotarget. 2018 Jul 20;9(56):30855-30868. doi: 10.18632/oncotarget.25762.

Diffusion-weighted imaging in monitoring the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis.

World J Surg Oncol. 2018 Jul 18;16(1):145. doi: 10.1186/s12957-018-1438-y.

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

PLoS One. 2018 May 23;13(5):e0197754. doi: 10.1371/journal.pone.0197754. eCollection 2018.

本文引用的文献

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35. doi: 10.1007/s00259-010-1640-9. Epub 2010 Nov 6.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Ann Surg Oncol. 2010 Sep;17(9):2411-8. doi: 10.1245/s10434-010-1008-1. Epub 2010 Apr 6.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

J Clin Oncol. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. Epub 2010 Feb 1.

Estimates of cancer incidence and mortality in Europe in 2008.

Eur J Cancer. 2010 Mar;46(4):765-81. doi: 10.1016/j.ejca.2009.12.014. Epub 2010 Jan 29.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.

Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.

Cancer. 2010 Feb 15;116(4):805-13. doi: 10.1002/cncr.24820.

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1551-7. doi: 10.1007/s00259-009-1116-y. Epub 2009 Mar 27.

The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Eur Radiol. 2009 Jun;19(6):1347-57. doi: 10.1007/s00330-009-1303-z. Epub 2009 Feb 13.

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.

J Clin Oncol. 2009 Feb 1;27(4):535-41. doi: 10.1200/JCO.2008.17.2650. Epub 2008 Dec 15.

The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2320-33. doi: 10.1007/s00259-008-0874-2. Epub 2008 Aug 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验